论文部分内容阅读
目的了解不同肥胖亚型的临床特点;探讨不同肥胖亚型的临床转归.方法收集湖南省人民医院体检中心2006年4月～2010年1月体检人群共4 067例,排除资料不全者,共2 830例纳入研究.其中1 367例于1～3年后再次来我院体检.结果 (1)在1 120例肥胖体检人群中,MHO占23.30%,肥胖伴单个代谢异常者占45.27%,肥胖伴MS占31.43%.(2)MHO组收缩压、舒张压、FBG、TG、ALT、尿酸、WBCC均高于(HDL低于)正常对照组,低于(HDL高于)肥胖伴MS组(P<0.05).肥胖伴单个代谢异常组收缩压、舒张压、FBG、TG、ALT均高于(HDL低于)MHO组,低于(HDL高于)肥胖伴MS组(P<0.05).(3)随访1～3年后,MHO代谢异常性疾病的发病率高于正常对照(46.79%vs 17.60%,P<0.05),OR值为4.117(95%CI:2.503～6.770;P<0.05);肥胖伴单个代谢异常组MS的发病率高于MHO(22.94%vs 7.34%),OR值为3.751,(95%CI,1.719～8.221;P<0.05).结论(1)在肥胖体检人群中MHO约占1/4,肥胖伴单个代谢异常者约占1/2,肥胖伴MS占1/3.(2)MHO临床表型介于正常对照与肥胖伴MS者之间,肥胖伴单个代谢异常者临床表型介于MHO与肥胖伴MS者之间.(3)随访1～3年后,MHO发生代谢异常性疾病的风险高于正常对照,肥胖伴单个代谢异常者发生MS的风险高于MHO.
Objective To understand the clinical features of different obesity subtypes and explore the clinical outcome of different obesity subtypes.Methods A total of 4 067 physical examination population from April 2006 to January 2010 in Hunan Provincial People’s Hospital Physical Examination Center were collected to exclude incomplete data 2 830 cases were included in the study, of which 1 367 cases returned to our hospital for physical examination after 1 to 3 years.Results (1) MHO accounted for 23.30% among the 1 120 obese medical examinations, 45.27% were obese with single metabolic abnormalities, (2) The systolic blood pressure, diastolic blood pressure, FBG, TG, ALT, uric acid and WBCC in MHO group were significantly higher than those in normal control group (lower HDL) than in obese MS group (P <0.05) .The systolic blood pressure, diastolic blood pressure, FBG, TG and ALT of obesity with single metabolic abnormality group were higher than those with MHO group and HDL lower than HDL group (P <0.05) . (3) After 1 to 3 years follow-up, the morbidity of metabolic abnormalities in MHO was higher than that in controls (46.79% vs 17.60%, P <0.05), and the odds ratio was 4.117 (95% CI: 2.503-6.770, P < 0.05). The incidence of MS in obesity with single metabolic abnormality group was higher than that in MHO (OR = 3.751, 95% CI, 1.719-8.221, P <0.05) MHO population accounts for about 1/4, obesity with a single metabolic abnormalities Accounting for 1/2, obesity with MS accounted for 1 / 3. (2) MHO clinical phenotype between the normal control and obesity with MS, obesity with a single metabolic abnormalities in the clinical phenotype between MHO and obesity with MS (3) After 1 to 3 years of follow-up, the risk of metabolic abnormalities in MHO was higher than that in normal controls, and the incidence of MS in obesity with single metabolic abnormalities was higher than that in MHO.